M&T Bank Corp Acquires New Holdings in AtriCure, Inc. (NASDAQ:ATRC)

M&T Bank Corp acquired a new stake in AtriCure, Inc. (NASDAQ:ATRC) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 6,799 shares of the medical device company’s stock, valued at approximately $208,000.

Other large investors have also added to or reduced their stakes in the company. State Street Corp raised its holdings in AtriCure by 4.9% in the 3rd quarter. State Street Corp now owns 1,344,856 shares of the medical device company’s stock valued at $37,710,000 after buying an additional 63,002 shares during the last quarter. Geode Capital Management LLC raised its holdings in AtriCure by 2.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company’s stock valued at $32,326,000 after buying an additional 32,676 shares during the last quarter. Atom Investors LP bought a new position in AtriCure in the 3rd quarter valued at approximately $1,741,000. Silver Oak Securities Incorporated bought a new position in AtriCure in the 4th quarter valued at approximately $220,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in AtriCure by 31.5% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company’s stock valued at $14,038,000 after buying an additional 119,929 shares during the last quarter. Institutional investors own 99.11% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on ATRC. Stifel Nicolaus raised their price target on shares of AtriCure from $36.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Canaccord Genuity Group boosted their price target on shares of AtriCure from $61.00 to $66.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Piper Sandler boosted their price target on shares of AtriCure from $40.00 to $50.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. boosted their price target on shares of AtriCure from $40.00 to $51.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Finally, Oppenheimer boosted their price target on shares of AtriCure from $36.00 to $45.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $51.56.

AtriCure Stock Up 1.7 %

AtriCure stock opened at $33.31 on Friday. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. AtriCure, Inc. has a 12-month low of $18.94 and a 12-month high of $43.11. The firm’s fifty day moving average is $38.10 and its 200 day moving average is $33.43. The company has a market capitalization of $1.63 billion, a PE ratio of -35.06 and a beta of 1.53.

Insider Activity at AtriCure

In other AtriCure news, Director Karen Prange sold 6,100 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the sale, the director now owns 17,828 shares in the company, valued at approximately $679,603.36. The trade was a 25.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.20% of the stock is owned by corporate insiders.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.